|Vilanterol||Ultra-long-acting β2 agonist|
|Trade names||Breo Ellipta, Relvar Ellipta|
|ATC code||R03AK10 (WHO)|
Fluticasone furoate/vilanterol (trade names Breo Ellipta and Relvar Ellipta) is a combination drug for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. It contains fluticasone furoate, an inhaled corticosteroid, and vilanterol, an ultra-long-acting β2 agonist (ultra-LABA).
In 2013, the drug was approved for use in the United States by the Food and Drug Administration for long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema, and the European Medicines Agency approved it as a second-line therapy for the treatment of COPD and asthma.
There are; however, concerns that LABAs such as vilanterol increase the risk of deaths due to asthma.
- "FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease". Food and Drug Administration. 10 May 2013.
- "Summary of opinion: Relvar Ellipta" (PDF). European Medicines Agency. 19 September 2013.
- Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) Official Site
- Breo Ellipta (fluticasone furoate and vilanterol) Inhalation Powder, for Oral Inhalation. U.S. Full Prescribing Information
|This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.|